Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Pulmonary Hypertension

Free Subscription 08.12.2025 1 Adv Sci (Weinh) 2 Am Heart J Plus 1 Ann Am Thorac Soc 1 Apoptosis 1 Biochem Pharmacol 1 Br J Pharmacol 2 Cardiol Young 1 Cardiovasc Drugs Ther 1 Cardiovasc Pathol 1 Cardiovasc Res 1 Chest 1 Circ Heart Fail 1 Circ Res 1 Clin Exp Hypertens 1 Clin Res Cardiol 1 Clin Transl Sci 1 Curr Probl Cardiol 1 Expert Rev Respir Med 1 Front Public Health 1 Int Heart J 1 J Cardiothorac Surg 1 J Clin Hypertens (Greenwich) 1 J Heart Lung Transplant 1 JA Clin Rep 1 Med Res Rev 1 Orv Hetil 1 Pediatr Pulmonol 1 Phytomedicine 3 Pulm Circ 1 Vascul Pharmacol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Sci (Weinh)

1. WU LW, Chen M, Jiang CY, Jiang DJ, et al
   Inactivation of AXL in Cardiac Fibroblasts Alleviates Right Ventricular Remodeling in Pulmonary Hypertension.
   Adv Sci (Weinh). 2025 Dec 3:e08995. doi: 10.1002/advs.202508995.
   PubMed         Abstract available
   
   

   
   Am Heart J Plus

2. NAING P, Scalia GM, Murdoch D, Ranasinghe I, et al
   Artificial intelligence enhanced contemporary pulmonary hypertension care.
   Am Heart J Plus. 2025;60:100673.
   PubMed         Abstract available
   
   
3. SI M, Hu Y, Jin Z, Mao Y, et al
   NF-kappaB and pulmonary hypertension: Advances in mechanistic research and therapeutic applications.
   Am Heart J Plus. 2025;60:100669.
   PubMed         Abstract available
   
   

   
   Ann Am Thorac Soc

4. MENON DP, Frantz RP, Gochanour BR, Beck GJ, et al
   Ground-Glass Opacities in Pulmonary Arterial Hypertension-Results from the PVDOMICS Study.
   Ann Am Thorac Soc. 2025;22:1863-1873.
   PubMed         Abstract available
   
   

   
   Apoptosis

5. MO Y, Wang D, Deng Z, Zhao P, et al
   Endothelial SPRY1 deficiency associates with angiogenic-metabolic reprogramming in pulmonary arterial hypertension: a multi-omics analysis of bulk and single-cell transcriptomic profiles.
   Apoptosis. 2025;30.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

6. CHEN N, Yin X, Wang D, Zhou D, et al
   Downregulation of KLF2 impairs pulmonary endothelial function and promotes persistent pulmonary hypertension of the newborn.
   Biochem Pharmacol. 2025 Nov 27:117572. doi: 10.1016/j.bcp.2025.117572.
   PubMed         Abstract available
   
   

   
   Br J Pharmacol

7. DIGNAM JP, Sharma S, Aitchison G, Gebril A, et al
   Cytochrome P450 1A1 influences obesity-induced pulmonary hypertension.
   Br J Pharmacol. 2025 Nov 30. doi: 10.1111/bph.70244.
   PubMed         Abstract available
   
   

   
   Cardiol Young

8. KIZILKAYA MH, Bilal MS, Gumus T, Celiker A, et al
   Inhaled iloprost and 2D phase-contrast cardiac MRI in pulmonary vascular reversibility: an adolescent case of anomalous right pulmonary artery from the ascending aorta.
   Cardiol Young. 2025;35:2353-2356.
   PubMed         Abstract available
   
   
9. KULSHRESTHA S, Rai P
   Isolated absence of the right pulmonary artery in a neonate: a rare but critical incidental diagnosis.
   Cardiol Young. 2025;35:2383-2386.
   PubMed         Abstract available
   
   

   
   Cardiovasc Drugs Ther

10. LIN C, Fu S, Li H, Zhang Y, et al
    RELM-beta Augmented Hypoxia-Induced Pulmonary Hypertension Through Interacting with GIPC1, OR1N1 and CLIC4.
    Cardiovasc Drugs Ther. 2025 Nov 29. doi: 10.1007/s10557-025-07816.
    PubMed         Abstract available
    
    

    
    Cardiovasc Pathol

11. ZHU M, Li G, Li Y, Chen J, et al
    Circ_0005372 targets the miR-153-3p/ITGB3 axis to stimulate the PI3K/AKT signaling pathway to facilitate the occurrence and development of congenital heart disease and pulmonary arterial hypertension in children.
    Cardiovasc Pathol. 2026;80:107768.
    PubMed         Abstract available
    
    

    
    Cardiovasc Res

12. NAMBIAR VEETIL N, Gransar T, Liu SF, Almalla A, et al
    Remodelling of the endothelial extracellular matrix promotes smooth muscle cell hyperplasia in pulmonary hypertension due to left heart disease.
    Cardiovasc Res. 2025 Dec 3:cvaf238. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Chest

13. CRAWFORD R, McLeod L, Yarr S, Morrison R, et al
    Initial Evaluation of the Pulmonary Hypertension Functional Classification Self-Report (PH-FC-SR) Measurement Properties: A Patient-Focused Measure.
    Chest. 2025 Nov 27:S0012-3692(25)05804-0. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Circ Heart Fail

14. REDDY YNV, Frantz RP, Hemnes AR, Hassoun PM, et al
    Prevalence and Clinical Implications of Excess Adiposity in Group 1 Pulmonary Hypertension.
    Circ Heart Fail. 2025 Dec 3:e013591. doi: 10.1161/CIRCHEARTFAILURE.125.013591.
    PubMed         Abstract available
    
    

    
    Circ Res

15. WOODCOCK CC, Maroli G, Kim H, Tai YY, et al
    Endothelial ADAR1 Deficit Induces the NOCT-IRF7 Axis in Pulmonary Hypertension.
    Circ Res. 2025 Dec 4. doi: 10.1161/CIRCRESAHA.125.326277.
    PubMed         Abstract available
    
    

    
    Clin Exp Hypertens

16. ZHENG Q, Zhao Z, Wang L, Yu C, et al
    Identification of endoplasmic reticulum stress-associated signatures of human pulmonary arterial hypertension: A bioinformatic analysis.
    Clin Exp Hypertens. 2025;47:2584570.
    PubMed         Abstract available
    
    

    
    Clin Res Cardiol

17. SHECHTER A, Gupta A, Kaewkes D, Taheri H, et al
    Mitral transcatheter edge-to-edge repair in patients with severe pulmonary hypertension.
    Clin Res Cardiol. 2025 Dec 4. doi: 10.1007/s00392-025-02796.
    PubMed         Abstract available
    
    

    
    Clin Transl Sci

18. WANG Y, Li X, Huang Z, Duan A, et al
    Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension.
    Clin Transl Sci. 2025;18:e70426.
    PubMed         Abstract available
    
    

    
    Curr Probl Cardiol

19. BRAVO-VASQUEZ MJ, Cueto-Robledo G, Roldan-Valadez E, Navarro-Vergara DI, et al
    In situ pulmonary arterial thrombosis in pulmonary arterial hypertension: Diagnostic differentiation, imaging criteria, and management-A narrative review with an institutional case-series snapshot.
    Curr Probl Cardiol. 2026;51:103209.
    PubMed         Abstract available
    
    

    
    Expert Rev Respir Med

20. ERSHED M, da Silva ABN, Felix de Farias Dos Santos AC, Heo D, et al
    Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.
    Expert Rev Respir Med. 2025;19:1273-1281.
    PubMed         Abstract available
    
    

    
    Front Public Health

21. LI L, Wang H, Chen Y, Tan X, et al
    Global burden of pulmonary arterial hypertension and health inequality in women of childbearing age from 1990 to 2021, with projections up to 2040: the global burden of disease 2021 study.
    Front Public Health. 2025;13:1700855.
    PubMed         Abstract available
    
    

    
    Int Heart J

22. YAMASHITA M, Saiki H, Saito K, Sato A, et al
    Volume Loading May Compromise Left Ventricular Filling in Patients with a Borderline Hypoplastic Left Ventricle.
    Int Heart J. 2025;66:1019-1024.
    PubMed         Abstract available
    
    

    
    J Cardiothorac Surg

23. CHEN P, Gong Q, Lu B, Zheng G, et al
    Surgical management of a patient with mirror-image dextrocardia with situs inversus, atrial septal defect, moderate tricuspid regurgitation, and moderate to severe pulmonary hypertension: a case report.
    J Cardiothorac Surg. 2025;20:445.
    PubMed         Abstract available
    
    

    
    J Clin Hypertens (Greenwich)

24. BASHIR A, Rizwan MA, Bashir M
    A Machine Learning-Based Model to Estimate the Risk of Pulmonary Hypertension in Chronic Kidney Disease Patients.
    J Clin Hypertens (Greenwich). 2025;27:e70190.
    PubMed        
    
    

    
    J Heart Lung Transplant

25. GHANI H, Pepke-Zaba J
    Old clots, new questions - the anticoagulation saga continues in chronic thromboembolic pulmonary hypertension.
    J Heart Lung Transplant. 2025 Nov 28:S1053-2498(25)02417.
    PubMed        
    
    

    
    JA Clin Rep

26. KAWAMOTO S, Miyao M, Sakurai K, Kato K, et al
    Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases.
    JA Clin Rep. 2025 Nov 29. doi: 10.1186/s40981-025-00834.
    PubMed        
    
    

    
    Med Res Rev

27. MO Y, Wang D, Bai Y
    Targeting PDGFR, EGFR, FGFR, and VEGFR: Key Receptor Tyrosine Kinases-Driven Metabolic Reprogramming in Pulmonary Arterial Hypertension.
    Med Res Rev. 2026;46:299-315.
    PubMed         Abstract available
    
    

    
    Orv Hetil

28. KOLODZEY G, Balogh L, Barta J, Peter A, et al
    [Chronic thromboembolic pulmonary hypertension - the hidden disease].
    Orv Hetil. 2025;166:1908-1915.
    PubMed         Abstract available
    
    

    
    Pediatr Pulmonol

29. AOYAMA BC, McGrath-Morrow SA, Collaco JM
    Bronchopulmonary Dysplasia Definitions As Predictors of Early Childhood Pulmonary Function.
    Pediatr Pulmonol. 2025;60:e71402.
    PubMed         Abstract available
    
    

    
    Phytomedicine

30. LU G, Sun H, Xu M, Fu C, et al
    Asiaticoside alleviates hypoxic pulmonary hypertension by regulating the voltage-gated potassium channel 1.5 through the protein tyrosine phosphatase non-receptor type 7 pathway.
    Phytomedicine. 2025;150:157595.
    PubMed         Abstract available
    
    

    
    Pulm Circ

31. TANNENBERG P, Tran-Lundmark K, Chang YT, Gladh H, et al
    Exploring the Impact of Platelet-Derived Growth Factor D in Pulmonary Hypertension Development.
    Pulm Circ. 2025;15:e70216.
    PubMed         Abstract available
    
    
32. ARUNACHALAM A, Guasch FM, Nayak T, John M, et al
    Pulmonary Arterial Wedge Oxygen Saturation: Does It Confirm Wedge Position in Patients With Pulmonary Hypertension?
    Pulm Circ. 2025;15:e70214.
    PubMed         Abstract available
    
    
33. GRIFFITHS M
    Beyond Resistance: Pulmonary Vascular Compromise as a Mechanistic Window Into Pediatric Pulmonary Hypertension.
    Pulm Circ. 2025;15:e70218.
    PubMed        
    
    

    
    Vascul Pharmacol

34. PAPA S, D'Alto M, Scelsi L, Acquaro M, et al
    ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score.
    Vascul Pharmacol. 2025 Nov 29:107561. doi: 10.1016/j.vph.2025.107561.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Pulmonary Hypertension is free of charge.